4:29 PM
 | 
Mar 17, 2014
 |  BC Extra  |  Clinical News

Intercept reports more data for obeticholic acid

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) fell $55.10 (12%) to $407.16 on Monday after disclosing in an SEC filing late Friday that there have been 10 serious cardiovascular adverse events occurring in seven patients receiving either once-daily obeticholic acid ( OCA) or placebo in the Phase II FLINT trial to treat non-alcoholic steatohepatitis (NASH). The update came after the company received blinded safety data from NIH's National Institute of Diabetes and Digestive and Kidney...

Read the full 346 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >